#Sorry: The World-leading Oncology Company fails in Phase III

23/10/2015 - 2 minutes

Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen‘s drug Kadcyla®, which has just failed in Phase III clinical trial to extend its indications. Here are the facts…

Antibody Drug Conjugate is at the boundary between chemical and biological drug. The principle is pretty simple; once the antibody fixes to its target, the cell-killing agent is released. Referring to our previous article, this brings an advantage compared to chemo because only tumors will be targeted and healthy cells are spared… Theoretically.

In this way, Roche’s partner Immunogen has combined Genentech‘s well-known antibody trastuzumab and its proprietary cell-killing agent DM1 (aka mertansine). First, it was designed to be used as a single agent for the treatment of patients with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane. With good outcomes in the trial, it had been approved by the FDA in February 2013 followed by the EMA approval in November of the same year.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member